DOCS vs. CURY, WOSG, CVSG, TIFS, DAL, AO, PPH, THG, CRN, and BOWL
Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Currys (CURY), Watches of Switzerland Group (WOSG), CVS Group (CVSG), TI Fluid Systems (TIFS), Dalata Hotel Group (DAL), AO World (AO), PPHE Hotel Group (PPH), THG (THG), Cairn Homes (CRN), and Hollywood Bowl Group (BOWL). These companies are all part of the "consumer cyclical" sector.
Dr. Martens (LON:DOCS) and Currys (LON:CURY) are both small-cap consumer cyclical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership.
73.3% of Dr. Martens shares are held by institutional investors. Comparatively, 92.2% of Currys shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Comparatively, 18.5% of Currys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Currys had 25 more articles in the media than Dr. Martens. MarketBeat recorded 30 mentions for Currys and 5 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 0.38 beat Currys' score of 0.29 indicating that Dr. Martens is being referred to more favorably in the media.
Dr. Martens has higher earnings, but lower revenue than Currys. Dr. Martens is trading at a lower price-to-earnings ratio than Currys, indicating that it is currently the more affordable of the two stocks.
Dr. Martens currently has a consensus price target of GBX 177.50, suggesting a potential upside of 108.82%. Currys has a consensus price target of GBX 77.80, suggesting a potential upside of 9.65%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Currys.
Dr. Martens has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, Currys has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Dr. Martens pays an annual dividend of GBX 6 per share and has a dividend yield of 7.1%. Currys pays an annual dividend of GBX 3 per share and has a dividend yield of 4.2%. Dr. Martens pays out 6,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Currys pays out 7,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.
Currys received 700 more outperform votes than Dr. Martens when rated by MarketBeat users. However, 91.67% of users gave Dr. Martens an outperform vote while only 77.88% of users gave Currys an outperform vote.
Dr. Martens has a net margin of 10.56% compared to Currys' net margin of 0.44%. Dr. Martens' return on equity of 29.07% beat Currys' return on equity.
Summary
Dr. Martens beats Currys on 12 of the 20 factors compared between the two stocks.
Get Dr. Martens News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Martens Competitors List
Related Companies and Tools
